REG - Concepta PLC - Change of name to MyHealthChecked Plc

MyhealthcheckedAnnouncement

02/12/2020 16:30

RNS Number : 3341H
  
Concepta PLC
  
02 December 2020
  
 

Concepta PLC
("Concepta" or the "Company") 
 
Change of name to MyHealthChecked Plc
 
Concepta PLC (AIM: CPT), the personalised healthcare company, confirms that it has today received confirmation from Companies House that its name has been changed and formally registered as MyHealthChecked Plc.
 
The Company expects that trading in the Company's shares under the new name will commence on 3 December 2020. The Company's ticker symbol will change to MHC. The Company's website can now be found at www.myhealthcheckedplc.com.
 
Shareholdings will be unaffected by the change of name and existing share certificates should be retained as they will remain valid for all purposes. Any new share certificates issued will bear the name MyHealthChecked Plc.
 
 



Concepta plc


www.conceptaplc.com




Penny McCormick, Chief Executive Officer


via Walbrook PR




Maddy Kennedy, Chief Financial Officer


















SPARK Advisory Partners Limited (NOMAD)


Tel: +44 (0)20 3368 3550




Neil Baldwin 


















Novum Securities (Joint Broker)


Tel: +44 (0)20 7399 9400




Colin Rowbury


















Oberon Capital Ltd (Joint Broker)


Tel: +44 (0)203 179 5344




Mike Seabrook


mikeseabrook@oberoninvestments.com














Walbrook PR Ltd (Media & Investor Relations)


Tel: +44 (0)20 7933 8780 or concepta@walbrookpr.com




Paul McManus


Mob: +44(0)7980 541 893 



 
 
About MyHealthChecked PLC (www.myhealthcheckedplc.com) 
MyHealthChecked PLC, based in Cardiff, is an AIM-quoted pioneering UK healthcare company with two diverse, customer-facing at-home testing brands in its portfolio:
 
MyHealthChecked is the umbrella brand of a range of at-home DNA and RNA tests, now in development following the recent acquisition of The Genome Store. The tests will be made available on line, and would be viable for over the counter purchase. 
 
The MyHealthChecked portfolio has been identified as part of a change in mindset as customers become more familiar with the concept of accessible healthcare in the growing at home testing kit market with a focus on accessibility at the right price, led by UK-based experts. 
 
Mylo targets the personalized mobile health market, with a primary focus on hormone testing and increasing a woman's chances of naturally getting pregnant, and providing insight to unexplained infertility. myLotus range of IVDs are CE-marked and are expected to be beneficial to users who have been unable to conceive after 6 months of trying. This highly motivated target group of women won't typically be offered medical intervention until after 12 months of unsuccessfully trying to conceive, with IVF not usually offered until after two years of trying to conceive. Research indicates couples start to take positive action ahead of this time typically with little medical support to help them do so.
 
myLotus range of IVDs are currently the UK's only consumer product which allows both quantitative and qualitative home (self-test) test measurement of a woman's personal luteinizing hormone (LH) during ovulation and human chorionic gonadotropin ("hCG") hormone level during pregnancy.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
  END
 
 
CANEAKAAEALEFFA